Table 4.
Association Between Dose of ACE Inhibitor Therapy Dispensed and the Outcomes During One Year of Follow-up for the 15,539 Older Adults Surviving 45 Days Past a New Heart Failure Admission Between January 1, 1998, and December 31, 1999, Using Two Sensitivity Analyses
| Hazard Ratio (95% CI) | ||||
|---|---|---|---|---|
| None | Low | Medium | High | |
| Mortality | ||||
| Intention-to-treat | 1.40 (1.29 to 1.52) | 1.00 | 0.94 (0.86 to 1.02) | 0.69 (0.63 to 0.76) |
| Time-dependent | 1.50 (1.38 to 1.63) | 1.00 | 1.05 (0.97 to 1.14) | 0.77 (0.70 to 0.84) |
| Mortality/Heart Failure Hospitalization | ||||
| Intention-to-treat | 1.13 (1.05 to 1.22) | 1.00 | 0.99 (0.93 to 1.06) | 0.86 (0.80 to 0.92) |
| Time-dependent | 1.14 (1.06 to 1.22) | 1.00 | 0.99 (0.93 to 0.06) | 0.86 (0.80 to 0.93) |
| Mortality/All Hospitalization | ||||
| Intention-to-treat | 1.01 (0.95 to 1.07) | 1.00 | 0.96 (0.91 to 1.01) | 0.85 (0.80 to 0.90) |
| Time-dependent | 1.00 (0.94 to 1.05) | 1.00 | 0.92 (0.88 to 0.97) | 0.83 (0.79 to 0.88) |
Low dose was the reference dose for all categories.
ACE, angiotensin-converting enzyme; CI, confidence interval.